Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke ...(ompared todosing in the unsuccessful Eur...),Health

Date:5/14/2008

ompared to dosing in the unsuccessful European Phase 3 trial. The analyses showed that European patients initially infused with Viprinex at the most rapid rate had statistically significant efficacy with Viprinex versus placebo. The analysis also showed that patients across both studies whose mean fibrinogen levels were kept above a certain threshold over the entire five to seven day treatment period had a rate of symptomatic intracranial hemorrhage that was substantially lower than in those with lower mean fibrinogen levels over the same five to seven day period. These data suggest that rapid initial lowering of fibrinogen is associated with better efficacy, but for safety purposes fibrinogen should be allowed to return back up to its higher level after treatment.

"Viprinex, a novel Fibrinogen Reducing Agent, is an enzyme that reduces levels of fibrinogen, the primary protein involved in blood clotting," said Warren W. Wasiewski, M.D., Vice President and Chief Medical Officer of Neurobiological Technologies, Inc. and a second author of the retrospective analysis. "Reducing fibrinogen in the blood lowers blood viscosity, which may improve blood flow. Additionally, as the fibrinogen is broken down, natural mechanisms are activated to dissolve blood clots that have already formed. Since Viprinex acts in the blood for a longer period of time than existing therapies for treatment of stroke, the effect of Viprinex on brain blood flow should be sustained longer. We believe that a single infusion of Viprinex would be better than a prolonged infusion for treating ischemic stroke."

Previous studies have shown that Viprinex can be effective when administered up to six hours after the onset of stroke symptoms, which could significantly expand the number of people who can be treated. The only currently approved drug therapy for ischemic stroke is limited to a three-hour window.

With more than 700,000 patients experiencing stroke each year in the United Stat
'/>"/>

SOURCE Neurobiological Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
2. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
3. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
4. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
5. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
6. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Napo Presents at ISPOR Meeting in Toronto
9. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
10. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
11. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C